| plz.spam.here@gmail.com 2005-10-06, 10:49 pm |
| This is strange and sad news. FTY720 has completed Phase II for
multiple sclerosis. After being on the drug for 6 months, 98% of the
255 patients on the drug chose to continue taking it. If there were
serious side effects like blindness, you would think the re-enrollment
would be much lower. Novartis is also planning Phase III so that all
had me hopinh the drug must be quite safe. The patients have been on
the drug for a year, some of them at 5mg/day.
Anyways a side-effect like blindness would be really unfortunate for a
drug as unique as FTY720!  The fact that it can be so useful for both
a chronic degenerate disease like MS as well as long-term graft-host
immunosuppresion makes it especially unfortunate.
What was your dose per day?
Source:
http://www.mydna.com/resources/clin...003_novmsd.html
|